J
Joshua Ö. Haznedar
Researcher at Hoffmann-La Roche
Publications - 5
Citations - 2201
Joshua Ö. Haznedar is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Sunitinib & Receptor tyrosine kinase. The author has an hindex of 5, co-authored 5 publications receiving 2149 citations.
Papers
More filters
Journal Article
In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship
Dirk B. Mendel,A. Douglas Laird,Xiaohua Xin,Sharianne G. Louie,James G. Christensen,Guangmin Li,Randall E. Schreck,Tinya Abrams,Theresa J. Ngai,Leslie Lee,Lesley J. Murray,Jeremy P. Carver,Emily Chan,Katherine G. Moss,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Robert A. Blake,Li Sun,Cho Tang,Todd W. Miller,Sheri Shirazian,Gerald Mcmahon,Julie M. Cherrington +22 more
TL;DR: The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.
Journal ArticleDOI
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Shem Patyna,A. Douglas Laird,Dirk B. Mendel,Anne-Marie O'Farrell,Christopher Liang,Huiping Guan,Tomas Vojkovsky,Stefan Vasile,Xueyan Wang,Jeffrey H. Chen,Maren Grazzini,Cheng Y. Yang,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Wei-Zhu Zhong,Julie M. Cherrington,Dana D. Hu-Lowe +16 more
TL;DR: Substantial data support the ongoing phase I clinical evaluation of SU14813 in advanced malignancies, a small molecule identified from the same chemical library used to isolate sunitinib, has broad-spectrum RTK inhibitory activity through binding to and inhibition of VEGFR, PDGFR, KIT, and FLT3.
Journal ArticleDOI
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
Joshua Ö. Haznedar,Shem Patyna,Carlo L. Bello,Geoffrey Peng,William Speed,Xiaoming Yu,Qingling Zhang,Juthamas Sukbuntherng,David J. Sweeny,Lida Antonian,Ellen Y. Wu +10 more
TL;DR: Sunitinib exhibited advantageous pharmacokinetic and dispositional properties in non-clinical species, translating into favorable properties in humans.
Journal ArticleDOI
Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.
Shem Patyna,Joshua Ö. Haznedar,David L. Morris,K. Freshwater,Geoffrey Peng,J. Sukbuntherng,Gary W. Chmielewski,Diane Matsumoto +7 more
TL;DR: As is typically observed for potent inhibitors of RTKs involved in angiogenesis, sunitinib was associated with embryo-fetal developmental toxicity in rats and rabbits at clinically relevant dose levels.
Journal ArticleDOI
Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS.
TL;DR: This method was applied to rat and dog plasma samples obtained from pharmacokinetic and toxicokinetic studies, and is fast, simple, sensitive, reproducible and has a wide linear range.